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To the Editor-in-Chief
Sir,
Hyperhydroxyprolinaemia: a new
case diagnosed during neonatal
screening with tandem mass
spectrometry
Hydroxyproline oxidase deficiency
(MIM 237000) is a rare autosomal
recessive defect in the catabolism of
the imino acid hydroxyproline derived
from endogenous collagen turnover
and the breakdown of dietary collagen.
The most important biochemical find-
ing is an increase in the hydroxyproline
plasmatic level with an abnormal urin-
ary excretion. Scanty data report
ambiguous information about clinical
involvement, such as mental retarda-
tion or visual perceptual dysfunc-
tion;1,2 they seem, therefore, to be
possibly due to analytical bias.3 Up to
now only one case of hydroxyprolinae-
mia diagnosed during newborn
screening has been reported.4
During expanded newborn screen-
ing in Tuscany using tandem mass
spectrometry (MS/MS),5,6 we diag-
nosed a newborn with hydroxyprol-
inaemia. The patient, a male, was born
at term (A.I. 9I–10V) to non-consangui-
neous parents from Tuscany, with a
weight of 2980 g after a pregnancy
during which diabetes was treated
with insulin. No clinical abnormalities
were found in his first days of life. His
dried blood spot was collected on the
third day of life and analysed during
the fourth day.
The dried blood spot was punched
into a micro 96-well plate, and 200 mL
of methanol containing labeled acyl-
carnitines and amino acid standards
were added. The sample was shaken
on a vortex system for 20 min. After
shaking, the extracted solution of
amino acids and acylcarnitines was
transferred to a new micro 96-well
plate, and was then dried under a
nitrogen flow at 508C. The extracted
acylcarnitines and amino acids were
derivatised to butyl esters using
n-butanol with HCl (3 M) at 658C for
25 min. After derivatisation the sam-
ple was dried under a nitrogen flow at
558C and then redissolved in 200 mL of
an aqueous solution of 50% acetoni-
trile containing 0.1% formic acid
(mobile phase) and 40 mL of the
diluted sample were injected using
flow injection analysis (FIA) for the
MS/MS experiments.
An Applied Biosystems-MDS Sciex
(Toronto, Canada) API 4000 triple-
quadrupole mass spectrometer equip-
ped with a TurboIonSpray source
was employed for this study. The
TurboIonSpray source was operated
in positive ion mode with a needle
potential of þ5900 V and with a
‘‘Turbo’’ gas flow of 10 L/min of air
heated at 1508C (nominal heating-gun
temperature). Mass calibration and
resolution adjustments on the resol-
ving quadrupoles were performed
automatically using a PPG solution
(104 mol/L) introduced via the built-
in infusion pump. The peak width was
set on both resolving quadrupoles at
0.7 Th (measured at 1/2 height) for all
MS and MS/MS experiments. Colli-
sionally activated dissociation (CAD)
MS/MS was performed in the LINAC
Q2 collision cell, operating with
10 mTorr pressure of nitrogen as colli-
sion gas. The declustering potential
(DP) and collision energy (CE) were
automatically optimised for amino
acids using the Analyst 1.4 software.
The resulting DP was þ20 V, and
optimal CE was found to be 32 eV
(laboratory frame) in the case of amino
acids.
MS and MS/MS spectra were col-
lected in continuous flow mode by
connecting the infusion pump directly
to the TurboIonSpray source. For these
optimisation experiments, a standard
solution of 10 ng/mL of each amino acid
in an aqueous solution of 50% acetoni-
trile containing 0.1% formic acid was
infused at 10mL/min.
The quantitation experiments were
performed using a series 1100 Agilent
Technologies (Waldbronn, Germany)
CapPump coupled to an Agilent Micro
mWS autosampler, both fully con-
trolled from the API 4000 data system.
The flow rate was 50mL/min using an
aqueous solution of 50% acetonitrile
containing 0.1% formic acid. The eluent
from the high-performance liquid
chromatography (HPLC) system was
directed to the TurboIonSpray probe.
The acquired data were processed
using the Analyst 1.4 proprietary soft-
ware including the ‘‘Explore’’ option
(for chromatographic and spectral
interpretation) and the ChemoView
software (for quantitative information
generation).
The amino acid analysis was per-
formed using a neutral loss scan in
the m/z range 130–280. In this case,
the leucine/isoleucine/hydroxypro-
line MS/MS signal (m/z 188.2! 86.1,
i.e. a neutral loss of 102.1 Da) was
unusually high (Fig. 1), indicating a
concentration of 390 mmol/L (normal
values (n.v.) 60–195, calculated as the
average 2 standard deviation (SD)
from 5000 newborn dried blood
spots) for the newborn spot, and to
412 mmol/L for the analysis of a sub-
sequent sample taken at 6 days of age.
The labelled internal standard was 2H3-
leucine (m/z 191.2! 89.1). The dried
urine spot analysed by the above
MS/MS screening method5,6 for dried
blood spots confirmed abnormal levels
up to 2742mmol/mmol creatinine (n.v.
0–143). Maple syrup urine disease
(MSUD, MIM 248600), a metabolic
disorder affecting the metabolism
of branched-chain amino acids,7 was
immediately excluded because no
abnormal valine level was detected.
Only two cases of hyperleuciniso-
leucinemia that were not associated
with the more common MSUD (normal
valine levels), but were associated with
hyperprolinemia type II, have been
described previously;8 these two de-
fects appear to be not correlated. How-
ever, in our case, quantitative amino
acid detection, using an HPLC-based
amino acid analyser (Biochrom20 plus,
Manchester, UK), confirmed an abnor-
mal hydroxyproline plasma level of
339 mmol/L (n.v. 16–53) and urinary
excretion of 2960mmol/mmol creati-
nine (n.v. 0–143). The patient was
clinically normal at 10th day of age,
and at 4 months the psychomotor
developmental, visual evocated poten-
tials, and fundus oculi were normal.
It was not possible to confirm the
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diagnosis by genomic analysis since, to
our knowledge, the hydroxyproline
oxidase gene has not yet been char-
acterized.
Profiles of acylcarnitines and amino
acids, obtained during newborn
screening with LC/MS/MS, permits
detection of more than 30 inborn errors
of metabolism. However, in some
cases, absence of specificity can be a
limitation. For example, drug interfer-
ences on acylcarnitine profiles have
been reported by Abdenur et al.9 In the
present case, butyl esters of leucine,
isoleucine and hydroxyproline are iso-
baric, with the same m/z value (188.2)
for the [MþH]þ ions and for their major
fragment ions (86.1), making their
differentiation by MS/MS impossible.
Therefore, it possible to draw a
general conclusion that this report
confirms that, in some cases, newborn
screening with tandem mass spectro-
metry is only the first diagnostic
approach, and that further confirma-
tory analytical tests are indispensable
to confirm the original diagnosis.
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Figure 1. Normal amino acid profile compared with one from a patient with hyperhydroxyprolinaemia.
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